BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam’s RNAi Platform Collaboration Update – at 2:00 p.m. ET on Monday, December 6, 2021.

Neurona Therapeutics, today announced that Catherine Priest, Ph.D., Neurona’s head of preclinical development, and David Blum, MD., Neurona’s head of clinical development, will present preclinical data that support the company’s recently cleared investigational new drug (IND) application and the initiation of the first-in-human Phase 1/2 clinical trial to evaluate lead asset, NRTX-1001.

CAMP4 Therapeutics today announced the presentation of in vivo proof-of-concept data demonstrating the potential therapeutic utility of

Encoded Therapeutics today announced initial findings from its ENVISION natural history study of children living with SCN1A+ Dravet syndrome, a rare developmental and epileptic encephalopathy.

Marizyme Inc. announced that it has received notice of allowance for foundational patent applications for two of its core technologies in several key markets further strengthening the company’s intellectual property.

ClaroNav, a leader in surgical navigation systems with a strong track record of growth and innovation, is pleased to announce that its CKI subsidiary has received Health Canada approval for its Navient ENT and Navient Cranial as Class III medical devices.

ACTIVITIES ARE UNDERWAY TO INITIATE US PHASE II IN HIP OSTEOARTHRITIS

Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that it has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of COVID-19.

Today, the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has signed agreements with Merck and Pfizer for access to their COVID-19 oral antiviral treatments.

UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the 75th American Epilepsy Society Annual Meeting (Chicago, Illinois), December 3-7, 2021.